News Search Results
May 19, 2025, 02:23 ET Ericsson to utilize mandate to transfer shares
time. Ericsson currently holds 38,390,417 shares of series B in the company and the maximum number of shares that may be transferred on Nasdaq Stockholm pursuant to the decision to utilize the authorization amounts to 368,692 shares of series B in the company. NOTES TO EDITORS: FOLLOW
More news about: Ericsson
May 19, 2025, 02:20 ET Ericsson to utilize mandate to transfer shares
time. Ericsson currently holds 38,390,417 shares of series B in the company and the maximum number of shares that may be transferred on Nasdaq Stockholm pursuant to the decision to utilize the authorization amounts to 368,692 shares of series B in the company. NOTES TO EDITORS: FOLLOW
More news about: Ericsson
May 15, 2025, 14:24 ET SignalRank Marks Two-Year Milestone with Strong Performance, Announces v4 of Investment Selection Model
investors and overseas equivalents35 Series B investments completed in 24 monthsSince making its first Series B investment in May 2023, SignalRank has emerged as the world's second most active Series B investor—trailing only Andreessen Horowitz in
More news about: SignalRank
May 15, 2025, 08:58 ET Alpheus Medical Raises $52M in Series B Round to Advance Groundbreaking Glioblastoma Therapy
therapy (SDT) for the treatment of solid body cancers, today announced the closing of an oversubscribed $52 million Series B financing round. The funds will support a Phase 2B randomized controlled trial (RCT) evaluating the efficacy of SDT
More news about: Alpheus Medical
May 15, 2025, 08:00 ET Sprinter Health Raises $55 Million To Expand Access To Preventive Care And Close Critical Care Gaps For People Nationwide
This Series B round led by General Catalyst, with investments from Andreessen Horowitz (a16z) and other prominent investors, will enable Sprinter Health to scale its tech stack, broaden its scope of services and engage more people in communities across the country
More news about: Sprinter Health
May 15, 2025, 08:00 ET S&W Announces Third Quarter Fiscal 2025 Financial Results
accrued for participating securities and accretion relates to dividends accrued for the Series B convertible preferred stock and the accretion for the discount related to the warrants issued in conjunction with the Series B convertible preferred stock. S&W believes it is useful to exclude these amounts
More news about: S&W Seed Company
May 14, 2025, 16:05 ET CoreWeave Reports Strong First Quarter 2025 Results
— Settlement of Series B tranche liability —
More news about: CoreWeave
May 14, 2025, 09:00 ET Aclima Adds to Executive Leadership Team to Expand Commercial Adoption of Air Monitoring Platform on Heels of Historic Deal and Funding
first-of-its-kind air monitoring fleet and measurement platform. The announcement follows the extension of Aclima's $40 million Series B funding and $13 million in contract financing from
More news about: Aclima
May 13, 2025, 16:15 ET Sunoco LP and NuStar Energy L.P. 2024 Schedule K-3s Now Available
an electronic copy of Schedule K-3 via email, NuStar Energy L.P. unitholders may call Tax Package Support toll free at (844) 364-7560 for Series A, Series B and Series C preferred units and (800) 310-6595 for common units weekdays between 8 a.m. and 5 p.m. CT. For more
More news about: Sunoco LP
May 13, 2025, 10:00 ET Octagos Launches OctaLink: AI-Optimized Cardiac Monitoring for Mobile Decision-Making
period of rapid customer growth, commercial expansion and technological innovation at Octagos. Backed by a $43 million Series B, the company is expanding device integration across ambulatory cardiac monitors, heart failure monitoring, and remote patient monitoring (RPM), while
More news about: Octagos Health, Inc.
May 13, 2025, 09:44 ET FEMSelect Poised for Market Leadership with Strategic Advancements in Women's Health
FEMSelect Announces Close of Oversubscribed Series B Equity Financing to Drive Commercial Growth, Leadership Transformation, and Global Expansion NEW YORK, May
More news about: FEMSelect
May 13, 2025, 09:00 ET Fincom Announces Series B Financing Led by Nasdaq Ventures with Participation from Macquarie Group and G1 Ventures
Fincom, a leader in anti-money laundering (AML) Sanction Screening and Entity Resolution technology, today announced the successful completion of its Series B funding round, securing a strategic investment led by
More news about: Fincom
May 13, 2025, 09:00 ET Thryv Therapeutics to Share Recent Clinical Results and Participate in Upcoming Healthcare Investor Conferences
NYThryv Therapeutics will participate in a fireside chat and host one-on-one meetings with investors about its future program plans and Series B financing throughout the conference. Jefferies Global Healthcare Conference 2025 Dates: June 3–5, 2025Location:
More news about: Thryv Therapeutics Inc.
May 13, 2025, 08:00 ET Cannabis Industry Revenue Grows Whilst Jobs Slightly Stall, Vangst Jobs Report Finds
on a mission to build the workforce infrastructure that powers it. Headquartered in Denver, CO, Vangst is a Series B company backed by Lerer Hippeau, Colle Capital, Level One Fund, Casa Verde Capital, and others. About Whitney Economics
More news about: Vangst
May 13, 2025, 08:00 ET VerifyMe Reports First Quarter 2025 Financial Results
Series B Convertible Preferred Stock, $0.001 par value; 85 shares authorized; 0.85 shares issued and outstanding as of March 31, 2025 and December
More news about: VerifyMe, Inc.
May 13, 2025, 05:00 ET Eligo Bioscience Awarded $5 Million to Advance Breakthrough Genetic Medicine Platform for Immuno-Dermatology
Nature, securing multiple foundational patents covering in situ editing of the skin microbiome, and successfully expanding its Series B funding round to $35 million. This latest non-dilutive financial support strengthens Eligo's capacity to rapidly advance
More news about: Eligo Bioscience
May 13, 2025, 05:00 ET Eligo Bioscience Awarded $5 Million to Advance Breakthrough Genetic Medicine Platform for Immuno-Dermatology
Nature, securing multiple foundational patents covering in situ editing of the skin microbiome, and successfully expanding its Series B funding round to $35 million. This latest non-dilutive financial support strengthens Eligo's capacity to rapidly advance
More news about: Eligo Bioscience
May 13, 2025, 02:31 ET Aker ASA: Aker Property Group acquires ownership interest in Public Property Invest ASA and Samhällsbyggnadsbolaget i Norden AB
community participation and social responsibility, municipalities and other stakeholders find the Company an attractive long-term partner. The Company's series B shares (ticker SBB B) and D shares (ticker SBB D) are listed on Nasdaq Stockholm, Large Cap. Further information about SBB is available at
More news about: Aker ASA
May 12, 2025, 14:38 ET Olio Raises $11M Series B Funding to Expand Product Innovation and Market Reach
-- Olio, the leading software platform streamlining care coordination, announced today the closing of an $11 million Series B funding round. The round was led by Fulcrum Equity Partners with participation from Mutual Capital Partners (MCP), a growth equity firm specializing
More news about: Olio
May 12, 2025, 09:15 ET X-Bow Systems Announces Final Closing of Over $105 Million Series B Funding to Deliver State-of-the-Art Defense Technologies at Speed and Scale
non-traditional producer of advanced manufactured solid rocket motors (SRMs) and defense technologies, today announced the successful final closing of its Series B funding round, totaling over $105 million. The strategic portion of this round was led by Lockheed Martin with a significant
More news about: X-Bow Systems
May 09, 2025, 07:00 ET Enbridge Reports Record Quarterly Results and Reaffirms 2025 Financial Guidance, Illustrating Its Industry Leading, Resilient Business Model
$0.34375 Preference Shares, Series B $0.32513
More news about: Enbridge Inc.
May 08, 2025, 16:05 ET Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
146,425 Series B non-voting convertible preferred stock, $0.0001 par value; 271,625 shares authorized and 16,667 shares issued and outstanding as of March 31, 2025
More news about: Spyre Therapeutics, Inc.
May 08, 2025, 16:05 ET Astrana Health, Inc. Reports First Quarter 2025 Results
Series B Preferred stock, zero authorized and issued and zero outstanding as of March 31, 2025 and zero authorized and issued and zero outstanding
More news about: Astrana Health, Inc.
May 08, 2025, 08:00 ET mPower Technology Closes Over $21M Series B Funding Round Led by Razor's Edge and Joined by Shield Capital
Technology, the leading provider of solar power solutions for space, announced it has secured over $21 million in Series B funding led by Razor's Edge Ventures and joined by Shield Capital. The new funding will be used to further scale production capacity, continue the
More news about: mPower Technology
May 08, 2025, 06:08 ET Sapiens Reports First Quarter 2025 Financial Results
Current maturities of Series B Debentures
More news about: Sapiens International